Article content

Tetra Bio-Pharma Inc. is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.

Tetra Bio-Pharma is a leader in cannabinoid-based drug discovery and development.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or Health Canada gives green light to Tetra Bio-Pharma’s Cannabis vs. Fentanyl Trial Back to video

The clinical trial will be conducted by Montreal-based Sante Cannabis, a medical clinic and contract research organization specialized in clinical research for cannabis- based therapies.

The trial will measure the time-to-relief in patients suffering from breakthrough cancer pain. Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel faster acting alternative to the opioid fentanyl. The time-to-maximal plasma concentrations of the THC suggest that PPP001 will provide rapid relief to the patients suffering.